ERBB2 and breast carcinoma: After defining the maximum tolerated dose (MTD) in the phase 1 dose escalation part of the trial, patients will be enrolled into several cohorts including HER2 positive breast cancer patients (cohort 1) and HER2-low breast cancer patients (IHC 1+ or 2+ but not HER2 amplified; escalation cohort 3).